Abstract
PPAR involvement in cell growth was investigated “in vivo” and “in vitro” and was correlated with cell proliferation and apoptotic death. “In vivo” PPAR
PPAR involvement in cell growth was investigated “in vivo” and “in vitro” and was correlated with cell proliferation and apoptotic death. “In vivo” PPAR
H. Kawamata, M. Tachibana, T. Fujimori, and Y. Imai, “Differentiation-inducing therapy for solid tumors,” Current Pharmaceutical Design, vol. 12, no. 3, pp. 379–385, 2006.
View at: Publisher Site | Google ScholarG. Chinetti, J.-C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation,” Inflammation Research, vol. 49, no. 10, pp. 497–505, 2000.
View at: Publisher Site | Google ScholarG. D. Girnun, W. M. Smith, S. Drori et al., “APC-dependent suppression of colon carcinogenesis by PPAR,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13771–13776, 2002.
View at: Publisher Site | Google ScholarR. A. Gupta and R. N. DuBois, “Controversy: PPAR as a target for treatment of colorectal cancer,” American Journal of Physiology. Gastrointestinal and Liver Physiology, vol. 283, no. 2, pp. G266–G269, 2002.
View at: Google ScholarA. Bernando and L. Minghetti, “PPAR- agonists as regulators of microglial activation and brain inflammation,” Current Pharmaceutical Design, vol. 12, no. 1, pp. 93–109, 2006.
View at: Publisher Site | Google ScholarR. Kostadinova, W. Wahli, and L. Michalik, “PPARs in diseases: control mechanisms of inflammation,” Current Medicinal Chemistry, vol. 12, no. 25, pp. 2995–3009, 2005.
View at: Publisher Site | Google ScholarT. Wang, J. Xu, X. Yu, R. Yang, and Z. C. Han, “Peroxisome proliferator-activated receptor in malignant diseases,” Critical Reviews in Oncology/Hematology, vol. 58, no. 1, pp. 1–14, 2006.
View at: Publisher Site | Google ScholarK. Yang, K.-H. Fan, S. A. Lamprecht et al., “Peroxisome proliferator-activated receptor agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice,” International Journal of Cancer, vol. 116, no. 4, pp. 495–499, 2005.
View at: Publisher Site | Google ScholarM. Lehrke and M. A. Lazar, “The many faces of PPAR,” Cell, vol. 123, no. 6, pp. 993–999, 2005.
View at: Publisher Site | Google ScholarR. Grau, C. Punzón, M. Fresno, and M. A. Iñiguez, “Peroxisome-proliferator-activated receptor agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1,” Biochemical Journal, vol. 395, no. 1, pp. 81–88, 2006.
View at: Publisher Site | Google ScholarM. Grabacka, P. M. Plonka, K. Urbanska, and K. Reiss, “Peroxisome proliferator-activated receptor activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt,” Clinical Cancer Research, vol. 12, no. 10, pp. 3028–3036, 2006.
View at: Publisher Site | Google ScholarN. Strakova, J. Ehrmann, J. Bartos, J. Malikova, J. Dolezel, and Z. Kolar, “Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors,” Neoplasma, vol. 52, no. 2, pp. 126–136, 2005.
View at: Google ScholarB. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2005.
View at: Publisher Site | Google ScholarR. Cunard, “The potential use of PPAR agonists as immunosuppressive agents,” Current Opinion in Investigational Drugs, vol. 6, no. 5, pp. 467–472, 2005.
View at: Google ScholarG. Martinasso, M. Maggiora, A. Trombetta, R. A. Canuto, and G. Muzio, “Effects of di(2-ethylhexyl) phthalate, a widely used peroxisome proliferator and plasticizer, on cell growth in the human keratinocyte cell line NCTC 2544,” Journal of Toxicology and Environmental Health, Part A, vol. 69, no. 5, pp. 353–365, 2006.
View at: Publisher Site | Google ScholarA. D. Burdick, D. J. Kim, M. A. Peraza, F. J. Gonzalez, and J. M. Peters, “The role of peroxisome proliferator-activated receptor-/ in epithelial cell growth and differentiation,” Cellular Signalling, vol. 18, no. 1, pp. 9–20, 2006.
View at: Publisher Site | Google ScholarH. Sampath and J. M. Ntambi, “Polyunsaturated fatty acid regulation of genes of lipid metabolism,” Annual Review of Nutrition, vol. 25, pp. 317–340, 2005.
View at: Publisher Site | Google ScholarM. Maggiora, M. Bologna, M. P. Cerù et al., “An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines,” International Journal of Cancer, vol. 112, no. 6, pp. 909–919, 2004.
View at: Publisher Site | Google ScholarG. Muzio, A. Trombetta, M. Maggiora et al., “Arachidonic acid suppresses growth of human lung tumor A549 cells through down-regulation of ALDH3A1 expression,” Free Radical Biology and Medicine, vol. 40, no. 11, pp. 1929–1938, 2006.
View at: Publisher Site | Google ScholarG. Muzio, G. Martinasso, A. Trombetta, D. Di Simone, R. A. Canuto, and M. Maggiora, “HMG-CoA reductase and PPAR are involved in clofibrate-induced apoptosis in human keratinocytes,” Apoptosis, vol. 11, no. 2, pp. 265–275, 2006.
View at: Publisher Site | Google ScholarV. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., “Peroxisome proliferator-activated receptor- activation inhibits tumor progression in non-small-cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004.
View at: Publisher Site | Google ScholarG. Muzio, M. Maggiora, A. Trombetta et al., “Mechanisms involved in growth inhibition induced by clofibrate in hepatoma cells,” Toxicology, vol. 187, no. 2-3, pp. 149–159, 2003.
View at: Publisher Site | Google ScholarR. A. Canuto, M. Maggiora, A. Trombetta, G. Martinasso, and G. Muzio, “Aldehyde dehydrogenase 3 expression is decreased by clofibrate via PPAR gamma induction in JM2 rat hepatoma cell line,” Chemico-Biological Interactions, vol. 143-144, pp. 29–35, 2003.
View at: Publisher Site | Google ScholarR. A. Canuto, M. Ferro, R. A. Salvo et al., “Increase in class 2 aldehyde dehydrogenase expression by arachidonic acid in rat hepatoma cells,” Biochemical Journal, vol. 357, no. 3, pp. 811–818, 2001.
View at: Publisher Site | Google ScholarJ. A. Brockman, R. A. Gupta, and R. N. DuBois, “Activation of PPAR leads to inhibition of anchorage-independent growth of human colorectal cancer cells,” Gastroenterology, vol. 115, no. 5, pp. 1049–1055, 1998.
View at: Publisher Site | Google ScholarR. A. Gupta, J. A. Brockman, P. Sarraf, T. M. Willson, and R. N. DuBois, “Target genes of peroxisome proliferator-activated receptor in colorectal cancer cells,” Journal of Biological Chemistry, vol. 276, no. 32, pp. 29681–29687, 2001.
View at: Publisher Site | Google ScholarS. Ulrich, S. M. Loitsch, O. Rau et al., “Peroxisome proliferator-activated receptor as a molecular target of resveratrol-induced modulation of polyamine metabolism,” Cancer Research, vol. 66, no. 14, pp. 7348–7354, 2006.
View at: Publisher Site | Google ScholarM. Mutoh, N. Niho, and K. Wakabayashi, “Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice,” Biological Chemistry., vol. 387, no. 4, pp. 381–385, 2006.
View at: Publisher Site | Google ScholarM.-Y. Li, T. W. Lee, A. P. C. Yim, and G. G. Chen, “Function of PPAR and its ligands in lung cancer,” Critical Reviews in Clinical Laboratory Sciences, vol. 43, no. 2, pp. 183–202, 2006.
View at: Publisher Site | Google ScholarT.-H. Chang and E. Szabo, “Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor in non-small cell lung cancer,” Cancer Research, vol. 60, no. 4, pp. 1129–1138, 2000.
View at: Google ScholarM. W. Matthiessen, G. Pedersen, T. Albrektsen, S. Adamsen, J. Fleckner, and J. Brynskov, “Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas,” Scandinavian Journal of Gastroenterology, vol. 40, no. 2, pp. 198–205, 2005.
View at: Publisher Site | Google ScholarN. Strakova, J. Ehrmann, J. Bartos, J. Malikova, J. Dolezel, and Z. Kolar, “Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors,” Neoplasma, vol. 52, no. 2, pp. 126–136, 2005.
View at: Google ScholarM.-C. Clemencet, G. Muzio, A. Trombetta et al., “Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate,” Cancer Letters, vol. 222, no. 2, pp. 217–226, 2005.
View at: Publisher Site | Google ScholarP. Zahradka, B. Wright, M. Fuerst, N. Yurkova, K. Molnar, and C. G. Taylor, “Peroxisome proliferator-activated receptor and ligands differentially affect smooth muscle cell proliferation and migration,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 2, pp. 651–659, 2006.
View at: Publisher Site | Google ScholarR. A. Roberts, S. Chevalier, S. C. Hasmall, N. H. James, S. C. Cosulich, and N. Macdonald, “PPAR and the regulation of cell division and apoptosis,” Toxicology, vol. 181-182, pp. 167–170, 2002.
View at: Publisher Site | Google ScholarJ. E. Klaunig, M. A. Babich, K. P. Baetcke et al., “PPAR agonist-induced rodent tumors: modes of action and human relevance,” Critical Reviews in Toxicology, vol. 33, no. 6, pp. 655–780, 2003.
View at: Google ScholarG. Icre, W. Wahli, and L. Michalik, “Functions of the peroxisome proliferator-activated receptor (PPAR) and in skin homeostasis, epithelial repair, and morphogenesis,” Journal of Investigative Dermatology, vol. 126, pp. 30–35, 2006.
View at: Google Scholar